Urine tests may be better than serum tests to diagnose multiple myeloma or its precursor conditions, because…
Ana Pena, PhD
Ana is a molecular biologist with a passion for discovery and communication. As a science writer, she looks for connecting the public, in particular patients and healthcare providers, with clear and quality information about the latest medical advances. Ana holds a Ph.D. in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in infectious diseases, epigenetics, and gene expression.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Ana Pena, PhD
MYELOMA
Twice‐weekly Ninlaro Combo Improves Outcomes in Newly Diagnosed Myeloma Patients, Trial Shows
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly…
Adding Pomalyst (pomalidomide) to a combination of Velcade…
The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a…
Selinexor, the lead oral therapy developed by Karyopharm…
SELLAS Life Sciences’ Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a…
Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery…